Objectives: Cooling following cardiac arrest can improve survival significantly. However, delays in achieving target temperature may decrease the overall benefits of cooling. Here, we test whether lipid emulsion, a clinically approved drug reported to exert cardioprotection, can rescue heart contractility in the setting of delayed cooling in stunned mouse cardiomyocytes. Design: Cell culture study. Setting: Academic research laboratory. Subjects: Cardiomyocytes isolated from 1-to 2-day-old C57BL6 mice. Interventions: Cardiomyocytes were exposed to 30 minutes of ischemia followed by 90 minutes of reperfusion and 10 minutes of isoproterenol with nine interventions: 1) no additional treatment; 2) intraischemic cooling at 32°C initiated 10 minutes prior to reperfusion; 3) delayed cooling started 20 minutes after reperfusion; 4) lipid emulsion + delayed cooling; 5) lipid emulsion (0.25%) administered at reperfusion; 6) lipid emulsion + intraischemic cooling; 7) delayed lipid emulsion; 8) lipid emulsion + delayed cooling + Akt inhibitor (API-2, 10 µM); and 9) lipid emulsion + delayed cooling + Erk inhibitor (U0126, 10 µM). Inhibitors were given to cells 1 hour prior to ischemia. Measurements and Main Results: Contractility was recorded by real-time phase-contrast imaging and analyzed with pulse image velocimetry in MATLAB (Mathworks, Natick, MA). Ischemia diminished cell contraction. The cardioprotective effect of cooling was diminished when delayed but was rescued by lipid emulsion. Further, lipid emulsion on its own improved recovery of the contractility to a greater extent as intraischemic cooling. However, cotreatment of lipid emulsion and intraischemic cooling did not further improve the recovery compared to either treatment alone. Furthermore, Akt and Erk inhibitors blocked lipid emulsion-induced protection. Conclusions: Lipid emulsion improved contractility and rescued contractility in the context of delayed cooling. This protective effect required Akt and Erk signaling. Lipid emulsion might serve as a treatment or adjunct to cooling in ameliorating myocardial ischemia/reperfusion injury. (Crit Care Med 2014; 42:e734-e740) 
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Infusion of lipid emulsion (ILE) has been reported to have similar protective effect to cooling with activation of Akt and Erk1/2 pathways (13, 14) , but has received little clinical attention. Jones et al (15) originally proposed the beneficial effects of the soybean-based ILE as a myocardial energy substrate after ischemic arrest, and Van de Velde et al (16, 17) demonstrated the benefit of a systemic infusion of ILE during recovery in several animal models of cardiac stunning. The use of ILE during resuscitation is advantageous from a practical standpoint since ILE are readily available, clinically approved (as a parenteral nutrition supplement), easily infused, and exhibit a favorable safety profiles (18) (19) (20) . These clinical advantages have led to the use to ILE as an effective treatment for cardiac pharmacotoxicity (21, 22) . Therefore, we hypothesized that ILE could be used as adjuvant to cooling, especially when delayed. We also compared the effect of ILE with intraischemic cooling (IC) and tested whether the combined treatment of ILE and cooling could further the cardiac protection in a cell model of myocardial stunning. Furthermore, we examined the effect of ILE on relevant signaling pathways.
MATERIALS AND METHODS
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health, and these procedures were approved by the Animal Care Committee at the University of Illinois at Chicago.
Mouse Cardiomyocyte Culture
Primary mouse ventricular cardiomyocytes were prepared from hearts of 1-to 2-day-old neonatal C57BL6 mice (Jackson Laboratories, Bar Harbor, ME). The details of the isolation protocol were reported previously (10) . Experiments were performed on culture day 6-8.
Ischemia Reperfusion Protocol
Synchronously contracting cells on glass coverslips were placed in a 1.2 ml Sykes-Moore perfusion chamber and subjected to ischemia reperfusion protocol as previously described (23) . Nine treatment groups were examined ( Fig. 1) and included 1) stunning (n = 10): cardiomyocytes were equilibrated for 30 minutes and then subjected to 30 minutes of simulated ischemia and 90 minutes of reperfusion followed by 10 minutes of isoproterenol (10 µM); 2) stunning + IC (n = 10): cooling (32°C) was initiated during the last 10 minutes of ischemia and extended 60 minutes into reperfusion; 3) stunning + delayed cooling (DC, n = 6): cooling was started 20 minutes into reperfusion and lasted for 40 minutes, and then rewarmed to 37°C for 30 minutes; 4) stunning + DC + ILE (20% Intralipid, Baxter Pharmaceuticals, Deerfield, IL): 0.25% ILE (diluted with balanced salt solution [BSS], n = 10) was administered at the reperfusion for 90 minutes (n = 11); 5) stunning + ILE (n = 10) was administered at the reperfusion for 90 minutes; 6) stunning + delayed infusion of lipid emulsion (DLE, n = 6) treatment: 0.25% ILE was administered at 20 minutes into reperfusion for 70 minutes; 7) stunning + IC + ILE (n = 5); 8) stunning + DC + ILE + API-2 (n = 5): cells were preincubated in API-2 (10 µM, EMD Chemicals, Philadelphia, PA) for 1 hour prior to ischemia; and 9) stunning + DC + ILE + U0126 (n = 5): cells were preincubated in U0126 (10 µM, EMD Chemicals, Philadelphia, PA) for 1 hour prior to ischemia. All reported time values are given as minutes following their specific treatment and include 30 minutes into equilibrium (Eq30), 5 minutes into ischemia (Is5), 10, 20, 30, 60, and 90 minutes into reperfusion (R10, R20, R30, R60, and R90, respectively), and 10 minutes into isoproterenol (Iso10). The Iso10 time point was used to assess the reserve capacity of contractility activated by β-adrenergic stimulation.
Measurement of the Contractile Velocity via Speckle Image Velocimetry
A Nikon ECLIPSE Ti inverted phase/fluorescent microscope (Nikon Instruments, Melville, NY) was used for cell imaging. Movement of cardiomyocytes was recorded with phase-contrast microscopy following the same field of cells over time. One field of cardiomyocytes (~500 cells) was selected for each experiment, and 8-second videos were acquired at predetermined time points using phase-contrast optics (20× magnification, 33 frames/s). Speckle Image Velocimetry (24) was used to quantify contraction velocity with custom-written MATLAB software (Mathworks, Natick, MA). Speckle image velocimetry method was similar to previously described methods (25) and focused on contractions of the entire collection of neonatal cardiomyocytes in a microscopic field as opposed to velocities within a single adult myocyte (26, 27) . In brief, a 19 × 19 array of 30 × 30 pixel (24 × 24 μm) windows to be tracked were spaced 25 pixels (20 μm) apart for reliable tracking of windows across contractions. Time of contraction onset for each video was identified based on peak differences in absolute pixel intensity between frames. Displacement matrices of each window were calculated using a fast-Fourier-Transform cross-correlation algorithm. Vector displacements were converted to velocities (μm/s) by dividing displacement by time step between frames (1/33 s). Maximum velocities were averaged across windows (n = 361) for each contraction, and mean contraction velocity was calculated by averaging all time points across the 8-second video. To ensure reproducibility, each set of experiments consisted of replicates (n between 5 and 11 as listed in the Ischemia Reperfusion Protocol section) generated from multiple batches of cells. To ensure consistency between batches, only cells with spontaneous contractions between 100 and 150 beats/min were used.
Western Blot Analysis
Protein was processed as previously described (10) . In brief, cells were lysed in lysis buffer. Samples were resolved using electrophoresis on a 10% sodium-dodecyl-sulfate polyacrylamide gel, transferred to a nitrocellulose membrane, and incubated with primary antibodies against p-Akt (T308 and S473), p-Erk1/2, or p-GSK3β S9 (Cell Signaling, Boston, MA) or α-tubulin (Neomarkers, Fremont, CA). The membranes were further incubated with secondary antibodies conjugated to horseradish peroxidase and visualized by SuperSignal (Thermo Scientific, Waltham, MA). Unless otherwise noted, lysates were analyzed at R30.
Statistical Analysis
Results are expressed as mean ± sem. Data were analyzed in Prism 6.0 (GraphPad, San Diego, CA). Before any individual comparisons; datasets were analyzed for normality using a D'Agostino and Pearson omnibus normality test if possible and using a Kolmogorov-Smirnov normality test if numbers were too low to perform the D'Agostino and Pearson. Before any group comparisons, groups were analyzed for equal variances using a Bartlett test for equal variance. When data were normal and exhibited equal variances, treatment groups were analyzed using a one-way analysis of variance with post hoc Bonferroni multiple comparison tests of selected time sets. If variances were unequal or data were nonnormal, treatment groups were analyzed with a Kruskal-Wallis test and post hoc Dunn multiple comparison tests. For intercondition comparisons, data during reperfusion (R10, R30, R60, and R90) were analyzed as a group; reserve capacity of contractility at the Iso10 time point was separated out and analyzed with a Mann-Whitney U test due to difference in test conditions relative to reperfusion time points. Differences from baseline (100% at Eq30) were assessed using a Wilcoxon rank-sum test.
RESULTS

Stunning After Ischemia and Reperfusion of Mouse Cardiomyocytes
The velocity of contractility at Eq30 was used as baseline (100%). Cell contraction stopped by Is5 with a relative contraction velocity of 3.5% ± 0.8% of baseline. It gradually recovered during reperfusion at R30 ( # p < 0.05), R60 ( § p < 0.0001), and R90 ( § p < 0.0001). The contractility was further improved with isoproterenol treatment to reflect the reserve capacity (p < 0.0001). However, it was not fully recovered to baseline level ( < p < 0.01) ( Fig. 2) .
Ischemic Cooling
Contractility aided by IC was analyzed by Kruskal-Wallis. IC did not improve contractility during reperfusion in contrast to stunning alone until R90 (60.6% ± 3.5% vs 41.8% ± 1.9%). Isoproterenol improved contractility to 107.9% ± 6.6%, which was indistinguishable from baseline, but was improved relative to that in stunning ( § p < 0.0001) ( Fig. 3A) . Delaying the cooling 20 minutes provided no benefit in contractility improvement compared to stunning alone ( Fig. 3B) .
Lipid Treatment
Supplementation of DC with ILE rescued the recovery of contractility ( Fig. 4A ) from 27.3% ± 2.3% to 40.77% ± 1.7% at R30 ( § p < 0.0001), from 35.3% ± 2.0% to 50.69% ± 1.8% at R60 ( § p < 0.0001), and from 39.3% ± 1.8% to 56.7% ± 3.1% at R90 ( § p < 0.0001). DC + ILE also preserved reserve capacity of contractility upon supplementation of isoproterenol (p < 0.0001). Further, treatment with 0.25% ILE alone resulted in a rapid and dramatic recovery ( Fig. 4B) . By R10, ILE markedly improved contractility (40.4% ± 2.8% vs 13.2% ± 1.9% in stunning alone, # p < 0.05), and the contractility remained elevated throughout reperfusion. Furthermore, reserve capacity was preserved and improved to 112% ± 4.2% at Iso10 (p < 0.0001). Perfusion with ILE in the Following reperfusion, contractility begins to recover by 30 min and is elevated from the total lack of contractility at ischemia 5 min (Is5) ( # p < 0.05) and continues to recover during reperfusion ( § p < 0.0001). R10 = 10 min of reperfusion, R30 = 30 min of reperfusion, R60 = 60 min of reperfusion, R90 = 90 min of reperfusion, Iso10 = 10 min of isoproterenol.
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Group Analysis
We analyzed overall recovery among all groups by comparing contractile levels of all conditions (stunning, DC, DLE, IC, ILE, DC + ILE, IC + ILE) at the R90 (Fig. 5A ) and the reserve contractile capacity at Iso10 (Fig. 5B) . At R90, ILE elevated contractile velocity the most in contrast to stunning ( § p < 0.0001), DC ( § p < 0.0001), and DLE ( § p < 0.0001), whereas IC elevated contractile velocity in contrast to stunning (p = 0.0291) and DC (p = 0.0352) and DLE (p = 0.0146). ILE induced a significantly higher contractile velocity than IC (75.0% ± 3.9% vs 60.6% ± 3.5%, # p < 0.0232). At Iso10, contractility was increased in IC, ILE, IC + ILE, and DC + ILE (p < 0.001) for all individual Bonferroni posttests compared with stunning, DC, and DLE while DC or DLE did not improve contractile reserve capacity. In comparison to baseline, IC and IC + ILE showed no difference at Iso10, but ILE recovered the contractility to above baseline level (p = 0.003). Further, coadministration of ILE and IC improved recovery compared with stunning (p < 0.001) but did not improve recovery beyond either treatment alone (Fig. 4, A and B) .
Assessment of Akt and Erk1/2 Involvement in Recovery
Probing for cellular signaling, we found that ILE increased p-Akt S473, T308, p-Erk1/2, and p-GSK3β S9 by R10, and this phosphorylation persisted throughout the reperfusion (Fig. 6A) . The protective effects of ILE were partially inhibited by either the Akt inhibitor API-2 (10 µM) or Erk inhibitor U0126 (10 µM) (Fig.  6B) . Figure 6C demonstrated that IC increased phosphorylation of Akt at T308 and S473, which was suppressed by DC. Cotreatment of ILE and DC reversed the effect of DC on p-Akt and was inhibited by API-2. Similarly, p-Erk1/2 was reduced by DC, increased by ILE, and inhibited by U0126 (Fig. 6D) .
DISCUSSION
We demonstrated in a cultured mouse cardiomyocyte model that a low concentration (0.25% or 0.25 g/100 mL) of a soy-based lipid emulsion given at reperfusion rescues recovery of contractility from ischemic stunning in the context of DC via activation of Akt and Erk1/2. This protection was blocked by specific inhibitors of Akt (API-2) or Erk1/2 (U0126). Further, the treatment of ILE improved rapidity and degree of contractile recovery and reserve capacity better than IC. These findings suggest that ILE can activate protective signaling pathways in heart cells similar to those activated by cooling and protect against stunning injury.
Stunning Model
We designed the shortened ischemia protocol to mimic the effects of cardiac stunning and assess the ability of different pharmacological interventions to maintain cardiac contractility after ischemia. The current work used a shortened protocol (30 min of ischemia) that diminished cardiac contractility in isolated cardiomyocytes and isoproterenol administration at the end of 90 minutes of reperfusion to assess the recovery of contractility and reserve capacity following stunning. This protocol demonstrated a consistent stunning effect and a time sensitivity of cooling protection (i.e., within 20 min of reperfusion) that has been reported in our mouse CA model. The 30-minute time period also reflects the 20-30 minutes of arrest seen in most human clinical therapeutic hypothermia studies. Previous work has demonstrated that a shortened protocol produces less cell death and lactate dehydrogenase release than longer protocols (23), but the current work confirmed that 30 minutes of ischemia severely reduces contractile capacity. Our work supports previous work, demonstrating that cooling can protect cardiac contractility against more prolonged detrimental periods of ischemia (28) .
Lipid Emulsion Rescue of Contractility via Akt and Erk
Administration of ILE at the start of reperfusion facilitated the rapid recovery of contractility in the stunned cardiomyocytes, and this effect depended on phosphorylation of Akt and Erk1/2. Previous work in isolated rat hearts demonstrated that ILE requires Akt signaling to exert myocardial protection (13, 29) , and we have previously demonstrated in both cell and mouse that benefit from cooling also requires Akt signaling (10, 11) . We confirmed in this stunning model that inhibiting Akt or Erk signaling pathways blocked the protective effects of ILE in promoting return of contractions following an ischemic insult. A common protective pathway shared by ILE and cooling might explain the rescue of contractility by ILE in the context of DC and the lack of synergistic effect with coadministration of IC and ILE. Previous studies have demonstrated that delivery of fatty acids or ILE during ischemia further exacerbates injury (30) (31) (32) (33) (34) (35) possibly owing to the increased oxygen requirements for fatty acid oxidation compared with glycolysis. The present study demonstrates that low-dose ILE delivered at reperfusion rapidly improves cardiomyocyte contractility, and in keeping with previous published findings (13, 29) , this protection is attributable to activation of survival signaling pathways. However, other studies suggest that β-oxidation is required for the beneficial effects of ILE (16) .
Clinical Implications
The prevalence of symptomatic coronary artery disease makes protecting the heart against lethal dysfunction after ischemic events a high priority for translational and clinical research. Reperfusion of ischemic myocardium can increase cellular damage and result in considerable morbidity and mortality (36) . Cooling has received interest, in part, because it confers neurological protection and has been recommended for patients who remain unconscious following return of spontaneous circulation after CA (37, 38) . Cardioprotective effects are also reported with intra-arrest cooling (39) when accompanying cardiopulmonary resuscitation (CPR) and is the subject of ongoing clinical investigations. However, the practical difficulties of rapidly achieving the targeted temperature management limit the clinical success of cooling (12) . An agent that could be given during or immediately following CPR to mimic cooling protection could potentially be very beneficial.
ILE was identified nearly 40 years ago as a potential treatment for cardiac stunning (15) (16) (17) , but never progressed to the clinical setting. Recently, there has been a renewed interest in the potential for ILE infusion to activate traditional cardioprotective pathways following stunning (13, 14) because of its success in treating cardiac pharmacotoxicity (40) partially through an improvement in contractility (41) . Previous experiments have described a benefit of ILE on the recovery from ischemic damage in patients (15) , conscious dogs (16) , isolated rabbit hearts (17) , and isolated rat hearts (13, 14, 29, 42) when delivered at reperfusion. Therefore, we assume that lipid treatment for cardiac dysfunction would most likely be used as an adjuvant in the setting of DC.
The loss of recovery of contractility when ILE was delayed further supports the concept of an early and critical window of opportunity for rescuing heart function and improving survival after CA. A similar window of protection has been seen in our mouse model of CA both with intra-arrest cooling during CPR (39) and with nitrite infusion (43) . These therapies all appear to . ILE given at reperfusion in the setting of DC improved contractility as early as 30 min of reperfusion (R30) during reperfusion ( § p < 0.0001) and at 10 min of isoproterenol (Iso10) ( § p < 0.0001). B, Effect of ILE improved cardiac contractility following stunning. Comparison of stunning (n = 10) and ILE treatment (n = 10). ILE improved contractility as early as 10 min of reperfusion (R10) ( # p < 0.05, ¶ p < 0.01) and at Iso10 ( § p < 0.0001). Eq30 = 30-min equilibration period, Is5 = ischemia 5 min, R60 = 60 min of reperfusion, R90 = 90 min of reperfusion. Figure 5 . A, Comparison of different treatment conditions at 90 min of reperfusion following stunning (n = 10). Intra-ischemic cooling (IC) (n = 10) improved contractility relative to stunning ( # p < 0.05), delayed cooling (DC) (n = 6, # p < 0.05) and delayed infusion of 0.25% lipid emulsion (DLE) (n = 6, # p < 0.05); infusion of 0.25% lipid emulsion at reperfusion (ILE) (n = 10) enhanced contractility in contrast to stunning ( § p < 0.0001), DC ( § p < 0.0001) and DLE ( § p < 0.0001). ILE was elevated above IC (p = 0.0232). Coadministration of IC and ILE (n = 5) showed no further improvement on contractility compared to either treatment alone. B, Comparison of different treatment conditions at 10 min of isoproterenol. IC, ILE, IC + ILE (n = 5), and DC + ILE (n = 11) were all elevated from stunning ( § p < 0.001), DC ( § p < 0.001), and DLE ( § p < 0.001). IC and IC + ILE showed no difference from baseline (p = 0.096 and p = 0.43, respectively). ILE was elevated above baseline (>p < 0.0039), while stunning, DC, DLE, and DC + ILE were still below ( # p < 0.05).
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In relevant animal CA models, ILE experiments would need to identify appropriate administration variables, efficacy, and safety.
A surprising aspect of the current work was the small concentration of lipid required to produce a substantial benefit in contractility. Previous studies have used larger concentrations (1%) of lipid emulsion to improve cardiac function in druginduced pharmacotoxicity (45, 46) , but here we show that 0.25% lipid emulsion was very effective at increasing recovery from stunning. For instance, a 0.25% final blood triglyceride concentration could be achieved with roughly a 30 mL bolus in a 70-kg patient-a dose much smaller than typically recommended for reversing local anesthetic toxicity (47) .
Limitations
We used an isolated cardiomyocyte model and therefore did not model the entire physiologic context of clinical CA. This cellular model lacks the systemic pharmacokinetic properties associated with lipid emulsion infusion and cannot account for the potential complications of a specific pathologic process like asphyxic arrest. However, this model does allow for careful study of stunning and its treatment at the cellular level apart from the systemic complexity of intact physiological models. Further, these heart cells rely less on fatty acids for metabolism than adult cells, which gives them an advantage to study ILE effects apart from metabolic substrate effects. A number of other experimental systems have exhibited a benefit in response to ILE during ischemic stunning including whole animal (16, 17) and whole organ (13, 14, 29) models. Additionally, these models have implicated a number of mechanisms including the requirement for β-oxidation (16), activation of the Akt and Erk (13, 29) , and mitochondrial effects (14, 29) . The only study demonstrating a negative effect examined lipid infusion in a rabbit model of hypoxic CA (48) where lipid was infused during asphyxia. Clearly, further preclinical studies are required before our results can be considered for translation to the clinical setting.
CONCLUSIONS
In a model of cardiac stunning using isolated cardiomyocytes, either IC (32°C) or lipid emulsion (0.25%) delivered at reperfusion improved contractile recovery during a 90-minute reperfusion. Additionally, lipid emulsion restored contractility much faster than any other treatment and served as an adjuvant in the case of DC, demonstrating cooling-like activation of the survival signaling pathways Akt and Erk1/2. The protective effect of IC or lipid emulsion was abolished when either was delayed just 20 minutes following reperfusion. This supports the notion of a critical time sensitivity for the treatment of stunning following CA. Figure 6 . Role of Akt and Erk in cardiac contractility following stunning. A, Infusion of 0.25% lipid emulsion at reperfusion (ILE) increased the phosphorylation of Akt S473, T308, Erk1/2, and GSK-3β-S9 during reperfusion analyzed by Western blot (n = 3). α-tubulin was used as a loading control. B, ILE-induced improvement on contractility in the context of delayed cooling (DC) was mediated by Akt and Erk activation. Akt inhibitor API-2 and Erk inhibitor U0126 blocked the enhancement of contractility in cells treated with ILE + DC compared with DC alone (n = 5, ¶ p < 0.01 and # p < 0.05, respectively). C, Effect of different treatments on Akt phosphorylation. Compared to stunning, intraischemic cooling (IC) increased p-Akt S473 and p-Akt T308 which were deactivated by DC, but reversed by ILE (n = 3). API-2 + balanced salt solution (BSS): cells were treated with API-2, but not subjected to stunning. D, Effect of different treatments on Erk phosphorylation. A similar effect was observed on Erk as on Akt (n = 3).
